HCC - HEPATOCELLULAR CARCINOMA
Clinical trials for HCC - HEPATOCELLULAR CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HCC - HEPATOCELLULAR CARCINOMA trials appear
Sign up with your email to follow new studies for HCC - HEPATOCELLULAR CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immunotherapy combo aims to stop liver cancer from coming back after ablation
Disease control OngoingThis study tests whether giving two immunotherapy drugs (durvalumab and tremelimumab) before a standard tumor-burning procedure, followed by a year of maintenance immunotherapy, can reduce the chance of liver cancer returning. About 30 adults with early-stage liver cancer will re…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated May 26, 2026 12:08 UTC
-
Triple therapy shows promise for tough liver cancers
Disease control OngoingThis study looked at 17 adults with intermediate to advanced liver cancer that could not be removed by surgery. They received a sequence of three treatments: a procedure to block the tumor's blood supply (TACE), precise radiation (SBRT), and drugs that help the immune system atta…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
Universal CAR-T cells take on advanced liver and lung cancer in early trial
Disease control TerminatedThis early-phase study tests a new type of immune cell therapy called universal CAR-T cells for people with advanced liver or lung cancer who have not responded to standard treatments. The therapy targets a protein called GPC3 found on these cancer cells. The main goals are to fi…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: EARLY_PHASE1 • Sponsor: Wondercel Biotech (ShenZhen) • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests an experimental drug called DECOY20, given alone or with another drug (tislelizumab), in about 120 adults with advanced solid tumors like liver, colorectal, pancreatic, lung, head and neck, bladder, or MSI-high cancers. The main goals are to check saf…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Indaptus Therapeutics, Inc • Aim: Disease control
Last updated May 18, 2026 11:58 UTC
-
AI predicts where liver cancer will spread next
Knowledge-focused OngoingThis study looks at whether a computer program (machine learning) can help predict if liver cancer will spread to the lungs or bones. Over 1,500 adults with liver cancer but no signs of spread at the start were followed during their regular care. The goal is to see if the tool's …
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Sponsor: Tongji Hospital • Aim: Knowledge-focused
Last updated May 26, 2026 12:06 UTC